Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Direct Functional Link Found for Two Parkinson Genes
28 June 2001. The two most prominent genes linked to inherited, monogenic Parkinson's disease-α-synuclein and parkin-are generally thought to be unconnected to each other because the forms of PD they cause are clinically and neuropathologically different. Yet in an article posted today on Science Express (http://www.sciencexpress.org), co-first authors Hideki Shimura and Michael Schlossmacher, working with Dennis Selkoe and Kenneth Kosik at Harvard Medical School's Center for Neurologic Diseases, report that the two proteins interact in a biochemical reaction. Moreover, they suggest that this reaction may underlie the aggregation of α-synuclein in conventional PD as well.

Their work centers on protein degradation. In this cascade of events, a series of enzymes dubbed E1, E2, and E3 activate and attach a chain of ubiquitin proteins to a substrate, tagging it for destruction in the proteasome. Last year Shimura et al. had shown parkin to be an E3 ligase. This and other findings raised the possibility that wildtype parkin might ubiquitinate α-synuclein, and that disease-linked mutations in parkin prevent this step toward the protein's proper disposal, said Schlossmacher. (α-synuclein is the abundant brain protein present in the neuronal "Lewy body" inclusions that characterize the most common, idiopathic form of PD.)

The paper reports four experiments supporting this idea. The authors found that α-synuclein and parkin co-localize in Lewy bodies of PD patients. They immunoprecipitated a protein complex from normal human brain, which contains parkin, an associated E2 enzyme, and a new, glycosylated form of α-synuclein (α-Sp22) as parkin's substrate. Next, the authors found that this brain-derived parkin specifically ubiquitinates α-Sp22 whereas mutant parkin from patients does not. Finally, the authors report that non-ubiquitinated α-Sp22 accumulated in parkin-deficient brains.

These findings suggest a hypothetical model to explain how inherited and sporadic forms of PD might arise from different alterations of the same underlying metabolic pathway, says Schlossmacher. In this view, loss of parkin would lead to accumulation of α-Sp22, which does not aggregate but might be neurotoxic. These patients do not have Lewy bodies but do have early onset of symptoms. In conventional PD, functioning parkin ubiquitinates α-Sp22 but subsequently, insufficient degradation would lead to a more gradual accumulation of polyubiquitinated α-Sp22, which tends to aggregate. These patients have Lewy bodies and late onset of symptoms.

The authors note that their data parallel findings reported in 1999 by Huda Zoghbi's group on the pathogenesis of polyglutamine expansions in the ataxin-1 gene. Mice expressing this mutated gene develop neuronal inclusions. When bred to lack the ataxin-1-specific E3 ligase, however, they show fewer inclusions but more severe neurodegeneration.-Gabrielle Strobel.

Reference:Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of a-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001 July 13;293:263-269. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad